Skip to main content
Equibles
RYTM logo

RYTM · Rhythm Pharmaceuticals, Inc.

Track RYTM — free

Use RYTM with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about RYTM

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$115.48 -0.54 (-0.47%) At close · Aug 14
Market Cap
$7.95B
Shares
68.85M

Rhythm Pharmaceuticals, Inc. Earnings Call Transcripts

Every quarterly earnings call for Rhythm Pharmaceuticals, Inc. (RYTM) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲316.7% $4.28M −$40.86M '22 Q3 22-11-08 ▲383.8% $8.79M −$42.49M '22 Q4 23-03-01 ▲665.6% $11.47M −$52.18M '23 Q1 23-05-02 ▲112% $19.22M −$46.70M '23 Q2 23-08-01 ▲425.3% $22.50M −$44.16M '23 Q3 23-11-07 ▲175.7% $24.23M −$41.63M '23 Q4 24-02-22 ▲126.4% $25.97M −$141.37M '24 Q1 24-05-07 ▲51.3% $29.08M −$32.26M '24 Q2 24-08-06 ▲47.8% $33.25M −$43.64M '24 Q3 24-11-05 ▲72.6% $41.83M −$43.33M '24 Q4 25-01-10 ▲25.9% $32.70M −$49.50M '25 Q1 25-05-07 ▲66.8% $48.50M −$46.63M '25 Q2 25-08-05 ▲54.3% $51.30M −$52.90M '25 Q3 25-11-04 ▲36.9% $57.25M −$47.51M '25 Q4 26-02-26 ▲83.8% $60.11M −$55.64M '26 Q1 26-05-05 LATEST ▲46.9% $71.25M −$49.30M '26 Q2 26-08-04
Conference
Investor event
2026-09-09
Wells Fargo 21st Annual Healthcare Conference
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-08-12
Canaccord Genuity 46th Annual Growth Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-04
Rhythm Pharmaceuticals Q2 2026 Earnings Conference Call
Confident tone International expansion U.S. HO launch CHI program and pipeline expansion
Revenue
$71.25M
▲ 46.9% YoY
Diluted EPS
$-0.73
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-05
Rhythm Pharmaceuticals, Inc. Q1 FY2026 Earnings Call
Confident tone Acquired hypothalamic obesity (HO) launch U.S. commercial execution and payer access BBS base business performance
Revenue
$60.11M
▲ 83.8% YoY
Diluted EPS
$-0.83
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Rhythm Pharmaceuticals, Inc. Q4 FY2025 Earnings Call
Confident tone FDA interactions and PDUFA Bivamelagon (HO) phase 2 data and phase 3 planning EMANATE trial program (genetic indications)
Revenue
$57.25M*
▲ 36.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Rhythm Pharmaceuticals, Inc. Q3 FY2025 Earnings Call
Confident tone IMCIVREE commercial growth (BBS) Acquired hypothalamic obesity (HO) launch Prader-Willi syndrome (PWS) Phase II
Revenue
$51.30M
▲ 54.3% YoY
Diluted EPS
$-0.82
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Rhythm Pharmaceuticals, Inc. Q2 FY2025 Earnings Call
Confident tone BBS commercial growth (IMCIVREE) Prader-Willi development Acquired hypothalamic obesity (HO) regulatory progress
Revenue
$48.50M
▲ 66.8% YoY
Diluted EPS
$-0.75
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Rhythm Pharmaceuticals, Inc. Q1 FY2025 Earnings Call
Confident tone BBS commercial performance (IMCIVREE) Phase 3 HO trial and regulatory filing Pipeline readouts (bivamelagon, PWS, RM-718)
Revenue
$32.70M
▲ 25.9% YoY
Diluted EPS
$-0.81
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-01-10
Rhythm Pharmaceuticals, Inc. Q4 FY2024 Earnings Call
Confident tone Phase II Bivamelagon Trial Readout Prader-Willi Syndrome Program Bardet-Biedl Syndrome (BBS) Commercial Opportunity
Revenue
$41.83M*
▲ 72.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-05
Rhythm Pharmaceuticals, Inc. Q3 FY2024 Earnings Call
Confident tone IMCIVREE commercial execution and revenue growth DAYBREAK trial results in genetic variants of obesity International expansion and country launches
Revenue
$33.25M
▲ 47.8% YoY
Diluted EPS
$-0.73
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Rhythm Pharmaceuticals, Inc. Q2 FY2024 Earnings Call
Confident tone BBS commercial execution International expansion and pricing Hypothalamic obesity Phase 3 trial
Revenue
$29.08M
▲ 51.3% YoY
Diluted EPS
$-0.55
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Rhythm Pharmaceuticals, Inc. Q1 FY2024 Earnings Call
Positive tone BBS Commercial Execution International Expansion Next-Generation Pipeline
Revenue
$25.97M
▲ 126.4% YoY
Diluted EPS
$-2.35
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-22
Rhythm Pharmaceuticals, Inc. Q4 FY2023 Earnings Call
Confident tone U.S. commercial performance and BBS launch Hypothalamic obesity Phase 3 trial International expansion (Europe)
Revenue
$24.23M*
▲ 175.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Rhythm Pharmaceuticals, Inc. Q3 FY2023 Earnings Call
Revenue
$22.50M
▲ 425.3% YoY
Diluted EPS
$-0.76
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-01
Rhythm Pharmaceuticals, Inc. Q2 FY2023 Earnings Call
Revenue
$19.22M
▲ 112% YoY
Diluted EPS
$-0.82
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-02
Rhythm Pharmaceuticals, Inc. Q1 FY2023 Earnings Call
Revenue
$11.47M
▲ 665.6% YoY
Diluted EPS
$-0.92
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-01
Rhythm Pharmaceuticals, Inc. Q4 FY2022 Earnings Call
Revenue
$8.79M*
▲ 383.8% YoY
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Rhythm Pharmaceuticals, Inc. Q3 FY2022 Earnings Call
Revenue
$4.28M
▲ 316.7% YoY
Diluted EPS
$-0.79
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-02
Rhythm Pharmaceuticals, Inc. Q2 FY2022 Earnings Call
Revenue
$9.07M
▲ 3208.8% YoY
Diluted EPS
$-0.89
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Rhythm Pharmaceuticals, Inc. Q1 FY2022 Earnings Call
Revenue
$1.50M
▲ 4180% YoY
Diluted EPS
$-1.05
▼ 216.7% YoY
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-01
Rhythm Pharmaceuticals, Inc. Q4 FY2021 Earnings Call
Revenue
$1.82M*
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Rhythm Pharmaceuticals, Inc. Q3 FY2021 Earnings Call
Revenue
$1.03M
Diluted EPS
$-0.70
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Rhythm Pharmaceuticals, Inc. Q2 FY2021 Earnings Call
Revenue
$274,000
Diluted EPS
$-0.70
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–23 of 23 earnings calls
Key facts CIK 1649904 CUSIP 76243J105 13F (30d) 284 filings 282 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)